Trials / Active Not Recruiting
Active Not RecruitingNCT05658237
Clinical Study of PAL-222 Targeting Patients With Myopic Chorioretinal Atrophy (PAMyCA)
Phase I/IIa Clinical Study of PAL-222 Targeting Patients With Myopic Chorioretinal Atrophy (PAMyCA)
- Status
- Active Not Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 10 (estimated)
- Sponsor
- PharmaBio Corporation · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this clinical trial is to assess efficacy and safety in patients with myopic chorioretinal atrophy. The main question it aims to answer are: • Percentage of changes in the chorioretinal atrophic area Participants will be implanted one sheet of PAL-222 into the subretinal space through pars plana vitrectomy. Researchers will compare non-therapeutic eye to see if the changes is significant different.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Pars plana vitrectomy | One sheet of PAL-222 is implanted into the subretinal space of either of eyes through pars plana vitrectomy. |
Timeline
- Start date
- 2023-02-17
- Primary completion
- 2026-01-31
- Completion
- 2026-03-31
- First posted
- 2022-12-20
- Last updated
- 2025-08-15
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT05658237. Inclusion in this directory is not an endorsement.